In more recent analyses, first-line afatinib significantly improved PFS, time-to-treatment failure, and objective response rate (ORR) versus gefitinib in patients with EGFR mutation-positive NSCLC [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.